Supriya Lifescience Limited (NSE:SUPRIYA)

India flag India · Delayed Price · Currency is INR
580.85
-47.05 (-7.49%)
Mar 9, 2026, 3:30 PM IST
-9.81%
Market Cap 46.75B
Revenue (ttm) 7.35B
Net Income (ttm) 1.85B
Shares Out 80.48M
EPS (ttm) 23.04
PE Ratio 25.21
Forward PE 19.76
Dividend 1.00 (0.16%)
Ex-Dividend Date Sep 4, 2025
Volume 478,736
Average Volume 161,856
Open 617.00
Previous Close 627.90
Day's Range 573.40 - 618.85
52-Week Range 579.60 - 842.00
Beta 0.14
RSI 24.22
Earnings Date Feb 9, 2026

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1987
Employees 515
Stock Exchange National Stock Exchange of India
Ticker Symbol SUPRIYA
Full Company Profile

Financial Performance

In fiscal year 2025, Supriya Lifescience's revenue was 6.96 billion, an increase of 22.12% compared to the previous year's 5.70 billion. Earnings were 1.88 billion, an increase of 57.80%.

Financial Statements

News

There is no news available yet.